beta
Trial Radar AI
Clinical Trial NCT02134574 (HemoDiag) for Hematologic Malignancy is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Prospective Cohort With Hemopathy in Languedoc-Roussillon (HemoDiag) 500

Recruiting
Clinical Trial NCT02134574 (HemoDiag) is an observational study for Hematologic Malignancy that is recruiting. It started on 1 February 2014 with plans to enroll 500 participants. Led by University Hospital, Montpellier, it is expected to complete by 1 June 2033. The latest data from ClinicalTrials.gov was last updated on 4 January 2022.
Brief Summary
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Detailed Description
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.
Official Title

Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon

Conditions
Hematologic Malignancy
Other Study IDs
  • HemoDiag
  • 9011
NCT ID Number
NCT02134574
Start Date (Actual)
2014-02
Last Update Posted
2022-01-04
Completion Date (Estimated)
2033-06
Enrollment (Estimated)
500
Study Type
Observational
Status
Recruiting
Keywords
Lymphoma,
leukemia,
multiple myeloma,
hodgkin disease
Arms / Interventions
Participant Group/ArmIntervention/Treatment
hematologic malignancy
hematologic malignancy with a sampling of blood
Hematologic Malignancy
hematologic malignancy with a sampling of blood
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Survival with 2 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30
2 years
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Survival with 5 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30
5 years
Survival with 10 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC\_QLQ-C30
10 years
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Age over 18
  • Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
  • Having signed an informed consent
  • Affiliated with a social security scheme

  • Minor or major protected
  • Patients who have received treatment for hematological pathology
University Hospital, Montpellier logoUniversity Hospital, Montpellier
Study Central Contact
Contact: Valerie ROUILLE, [email protected]
1 Study Locations in 1 Countries
Hematology department - UHMontpellier Saint éloi, Montpellier, France
Valerie ROUILLE, Contact, [email protected]
GUILLAUME CARTRON, Principal Investigator
Recruiting